IgA nephropathy; Acute interstitial nephritis; Acute kidney injury; This literature-non-study case was reported in a literature article and describes the occurrence of IGA NEPHROPATHY (IgA nephropathy), TUBULOINTERSTITIAL NEPHRITIS (Acute interstitial nephritis) and ACUTE KIDNEY INJURY (Acute kidney injury) in a 44-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.       No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced IGA NEPHROPATHY (IgA nephropathy) (seriousness criterion medically significant), TUBULOINTERSTITIAL NEPHRITIS (Acute interstitial nephritis) (seriousness criterion medically significant) and ACUTE KIDNEY INJURY (Acute kidney injury) (seriousness criterion medically significant). At the time of the report, IGA NEPHROPATHY (IgA nephropathy), TUBULOINTERSTITIAL NEPHRITIS (Acute interstitial nephritis) and ACUTE KIDNEY INJURY (Acute kidney injury) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood albumin: 3.7 g/dl Laboratories during presentation 3.7 g/dl and 3.8 g/dl Laboratories during last follow-up 3.8 g/dl. On an unknown date, Blood creatinine: 1.1 mg/dl 1.1 mg/dl baseline, 2.5 g/dl during presentation 2.5 g/dl and 3.6 g/dl Laboratories during last follow-up 3.6 g/dl. On an unknown date, Protein urine: 14 g/d Laboratories during presentation 14 g/d and 5.6 g/d Laboratories during last follow-up 5.6 g/d. On an unknown date, Red blood cells urine: 21  30 high power field (hpf) Laboratories during presentation 21  30 HPF and 3-10 hpf Laboratories during last follow-up 3-10 HPF.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered IGA NEPHROPATHY (IgA nephropathy), TUBULOINTERSTITIAL NEPHRITIS (Acute interstitial nephritis) and ACUTE KIDNEY INJURY (Acute kidney injury) to be possibly related.    Patient was presented with Acute kidney injury and in follow up it was reported that patient was treated with high dose High-dose steroid. About 69% of patients in our case series developed AKI but majority of them developed AKI stage 1.  This is a literature case concerning a  44-year-old, male patient with no relevant history reported, who experienced the ,unexpected serious events of IGA NEPHROPATHY, TUBULOINTERSTITIAL NEPHRITIS and ACUTE KIDNEY INJURY . The event occurred approximately 2 weeks after the  1st dose of mRNA-1273 Moderna vaccine. The rechallenge was N/A (no information about 2nd dose was provided)   This case was linked to MOD-2021-357609, MOD-2021-357610, MOD-2021-357611, MOD-2021-357612, MOD-2021-357613, MOD-2021-357614 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 20-Oct-2021: Follow up received by safety 22-Oct-2021 included an Email with FTA received from team and does not contain any new information.; Sender's Comments: This is a literature case concerning a  44-year-old, male patient with no relevant history reported, who experienced the ,unexpected serious events of IGA NEPHROPATHY, TUBULOINTERSTITIAL NEPHRITIS and ACUTE KIDNEY INJURY . The event occurred approximately 2 weeks after the  1st dose of mRNA-1273 Moderna vaccine. The rechallenge was N/A (no information about 2nd dose was provided) The benefit-risk relationship of COVID19 MODERNA is not affected by this report.